Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 6,434 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Clear all
Completed Phase 3 Interventional

Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate

NCT00312117
View directory record Official record
Conditions
Contrast Induced Nephropathy, Kidney Diseases
Interventions
Sodium bicarbonate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 23, 2026, 6:51 AM EDT
Terminated Not applicable Interventional

Clipped Versus Handsewn Arteriovenous Fistula Anastomosis

NCT01669850
View directory record Official record
Conditions
Arteriovenous Fistula Complications and Failure
Interventions
Clipped anastomosis, Handsewn anastomosis
Device · Procedure
Lead sponsor
Gundersen Lutheran Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 3 Interventional

Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D

NCT02492620
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperphosphatemia, Iron Deficiency Anemia, Renal Insufficiency
Interventions
Ferric Citrate
Drug
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)

NCT00500682
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Placebo, AST-120
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
41
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Alhambra, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 23, 2026, 6:51 AM EDT
Recruiting Phase 3 Interventional

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

NCT07498335
View directory record Official record
Conditions
Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type
Interventions
Drug: Atrasentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Neptune City, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors

NCT01331135
View directory record Official record
Conditions
Ewing's Sarcoma, Osteosarcoma, Astrocytoma, Atypical Teratoid/Rhabdoid Tumor, Ependymoma, Germ Cell Tumor, Glioma, Medulloblastoma, Rhabdoid Tumor, Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Wilms Tumor, Hepatoblastoma, Neuroblastoma, Rhabdomyosarcoma
Interventions
sirolimus
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Not applicable Interventional Results available

Diet and Hypertension Management in African Americans With Chronic Kidney Disease

NCT04084574
View directory record Official record
Conditions
Chronic Kidney Diseases, High Blood Pressure
Interventions
DASH diet counseling
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 23, 2026, 6:51 AM EDT
Terminated Not applicable Interventional

Validation of Low Dose CT for Diagnosis of Urolithiasis

NCT03656913
View directory record Official record
Conditions
Nephrolithiasis, Ureterolithiases
Interventions
Extremely low dose CT
Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 20 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Not applicable Interventional Results available

Vitamin D and Arteriovenous Fistulae

NCT00912782
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 23, 2026, 6:51 AM EDT
Recruiting Not applicable Interventional

A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)

NCT06173323
View directory record Official record
Conditions
Decision Making, Shared, Family Caregiving, Chronic Kidney Disease
Interventions
ImPart - Improving Chronic Kidney Disease Decisional Partnerships
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis

NCT02341417
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Cinacalcet
Drug
Lead sponsor
Amgen
Industry
Eligibility
Up to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
18
States / cities
Los Angeles, California • Tucker, Georgia • Baltimore, Maryland + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

NCT02724020
View directory record Official record
Conditions
Clear-cell Metastatic Renal Cell Carcinoma
Interventions
Everolimus, MLN0128, MLN1117
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Los Angeles, California • Venice, Florida • West Palm Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 4 Interventional Results available

A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls

NCT01663740
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
Valganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
20 Years to 50 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Not applicable Interventional Results available

Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis

NCT03301740
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
UF profiling during HD, Conventional HD
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Carrboro, North Carolina • Siler City, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 23, 2026, 6:51 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Severe Sepsis in Children - IMPRESS-C

NCT02598674
View directory record Official record
Conditions
Acute Kidney Injury, Chronic Kidney Disease, Hypertension
Interventions
Iodohippurate, 24 hour ambulatory Blood Pressure, Peripheral Arterial Tonometry, Pulse Wave Velocity, Gadolinium
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 23, 2026, 6:51 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

NCT04953897
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
ASTX727
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

NCT05013008
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Finerenone (Kerendia, BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
13
States / cities
Northridge, California • Port Hueneme, California • Waterbury, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

NCT01759576
View directory record Official record
Conditions
Renal Insufficiency, Healthy
Interventions
Canagliflozin (JNJ-28431754)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment

NCT04486625
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Aztreonam-Avibactam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Cyclophosphamide and Fludarabine to Treat Lupus Nephritis

NCT00001676
View directory record Official record
Conditions
Glomerulonephritis, Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
SQ Fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 6:51 AM EDT
Completed No phase listed Observational Results available

Improving Screening and Therapy for Hispanic/Latinx at Risk for CKD

NCT05734989
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Kidney Diseases
Interventions
BP, HbA1c, PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD
Diagnostic Test · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 23, 2026, 6:51 AM EDT
Active, not recruiting Phase 4 Interventional

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

NCT05671991
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis
Interventions
Empagliflozin 25 mg vs Placebo, Empagliflozin 10 MG
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 6:51 AM EDT
Completed Not applicable Interventional Results available

A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making

NCT00122135
View directory record Official record
Conditions
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Cirrhosis, Colon Carcinoma, Lung Cancer, Chronic Kidney Disease
Interventions
Values Inventory (VI)
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 23, 2026, 6:51 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

NCT05487040
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332 (nirmatrelvir)/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
52
States / cities
Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 23, 2026, 6:51 AM EDT